ATRICURE INC

Insider Vinayak sells 6,000 AtriCure shares at $38.88, signaling cautious liquidity amid a 23% weekly rise and 46% monthly surge, but no warning of a downturn.

Insightful insider sale at AtriCure: Karen Prange sold 3,000 shares post‑grant, balancing liquidity while retaining long‑term confidence in the company’s biotech future.

Insider sale of 5,000 AtriCure shares by Chief Scientific Officer Doraiswamy Vinayak shows routine liquidation, not a warning of falling prospects.

Insider buying at AtriCure signals confidence in its cardiac device strategy, as execs purchase 250k+ shares after Q4 earnings beat expectations.